C. William Pike

Appearances

AMONG PATIENTS WITH IBD USE OF STATINS IS ASSOCIATED WITH LOWER RISK OF DEVELOPING DE NOVO PRIMARY SCLEROSING CHOLANGITIS
Date
May 19, 2024
BACKGROUND: Primary sclerosing cholangitis (PSC) is a progressive, cholestatic liver disease without medical cure, that confers a significantly elevated risk of malignancy, acute cholangitis and cirrhosis. Approximately 2-7% of patients with inflammatory bowel disease (IBD) will develop PSC…
Presenter
Chiraag Kulkarni
Stanford University
Speakers
C. William Pike
John Mark Gubatan
Saurabh Gombar
George Cholankeril
Aparna Goel
Sidhartha Sinha
GLP-1 AGONISTS CAN PREVENT LIVER DISEASE PROGRESSION IN PATIENTS WITH METABOLIC AND ALCOHOL-ASSOCIATED LIVER DISEASE (METALD).
Date
May 20, 2024
Background: The American Association for Study of Liver Diseases (AASLD) recently proposed new nomenclature to characterize steatotic liver diseases…
Presenter
Amir Gougol
Stanford University
Speakers
C. William Pike
Niloufar Khanna
Paul Yien Kwo